Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $25.9500 (0.86%) ($25.9500 - $25.9500) on Wed. Aug. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.31% (three month average) | RSI | 56 | Latest Price | $25.9500(0.86%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.9% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(61%) IWO(61%) ARKK(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.155% in a week (0% probabilities). VIXM(-46%) VXX(-40%) UUP(-20%) IGOV(-8%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.155% (StdDev 4.31%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $24.73(4.93%) | 10 Day Moving Average | $23.67(9.63%) | 20 Day Moving Average | $24.85(4.43%) | To recent high | -35.9% | To recent low | 19.7% | Market Cap | $3.287b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |